CA3066463A1 - Methods for treating merkel cell carcinoma (mcc) using nk-92 cells - Google Patents

Methods for treating merkel cell carcinoma (mcc) using nk-92 cells Download PDF

Info

Publication number
CA3066463A1
CA3066463A1 CA3066463A CA3066463A CA3066463A1 CA 3066463 A1 CA3066463 A1 CA 3066463A1 CA 3066463 A CA3066463 A CA 3066463A CA 3066463 A CA3066463 A CA 3066463A CA 3066463 A1 CA3066463 A1 CA 3066463A1
Authority
CA
Canada
Prior art keywords
cells
subject
administered
merkel cell
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3066463A
Other languages
English (en)
French (fr)
Inventor
Hans Klingemann
Tien Lee
Laurent BOISSEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantKwest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NantKwest Inc filed Critical NantKwest Inc
Publication of CA3066463A1 publication Critical patent/CA3066463A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3066463A 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells Abandoned CA3066463A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522335P 2017-06-20 2017-06-20
US62/522,335 2017-06-20
PCT/US2018/038308 WO2018236887A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Publications (1)

Publication Number Publication Date
CA3066463A1 true CA3066463A1 (en) 2018-12-27

Family

ID=62875317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066463A Abandoned CA3066463A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Country Status (9)

Country Link
US (1) US20200171087A1 (https=)
EP (1) EP3641790A1 (https=)
JP (1) JP2020524164A (https=)
KR (1) KR20200017494A (https=)
CN (1) CN110753551A (https=)
AU (1) AU2018288712A1 (https=)
CA (1) CA3066463A1 (https=)
IL (1) IL270838A (https=)
WO (1) WO2018236887A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134085B1 (en) 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use

Also Published As

Publication number Publication date
WO2018236887A1 (en) 2018-12-27
AU2018288712A1 (en) 2019-12-12
JP2020524164A (ja) 2020-08-13
CN110753551A (zh) 2020-02-04
EP3641790A1 (en) 2020-04-29
US20200171087A1 (en) 2020-06-04
KR20200017494A (ko) 2020-02-18
IL270838A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
Najafi et al. The current knowledge concerning solid cancer and therapy
Yang et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
Levy et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
Carvalho et al. Radiotherapy and immune response: the systemic effects of a local treatment
Den Otter et al. Local therapy of cancer with free IL-2
Siu et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
AU2013208649B2 (en) Combination therapy for the treatment of cancer
JP2019196394A (ja) がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム
Cerna et al. SMAC Mimetic/IAP inhibitor birinapant enhances radiosensitivity of glioblastoma multiforme
Guo et al. Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients
US20200171087A1 (en) Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
Fiveash et al. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
Geoerger et al. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study
US20200121720A1 (en) Nk-92 cells and il-15 agonist combination therapy
Eisen et al. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
CA3167134A1 (en) Methods for enhancing t cells using venetoclax
HK40022820A (en) Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy
WO2021228983A1 (en) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
Zheng et al. Advances in classification and treatment of primary cutaneous lymphomas
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
Choi et al. SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH MEK INHIBITOR AND PI3K/MTOR DUAL INHIBITOR IN CASTRATION-RESISTANT PROSTATE CANCER IN VIVO AND EX VIVO: PD32-08
Husieva et al. Drug classification for the treatment of hematologic malignancies
Weldon et al. Treatment of Cutaneous Lymphomas: Topical, Systemic, and Radiation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201026

FZDE Discontinued

Effective date: 20230321